Home Featured Page 213

Featured

Latest

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

PT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood

Psychedelic Research Bulletin: September 2021

Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase...

PTSF81 – Somatics, Reframing Trauma, and the 7 Lens Approach, with...

MindMed Joins Clinical Trials Transformation Initiative

The Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex...

Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the...

Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of...

1...212213214...301 Page 213 of 301

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

PT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood

Psychedelic Research Bulletin: September 2021

Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase...

PTSF81 – Somatics, Reframing Trauma, and the 7 Lens Approach, with...

MindMed Joins Clinical Trials Transformation Initiative

The Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex...

Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the...

Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of...

EDITOR PICKS

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY